Affinity DataKi: 1.40nMAssay Description:Inhibition of human recombinant IDE-mediated fluorescein-Abeta-(1-40)-Lys-biotin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 3nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 22nMAssay Description:Inhibition of human recombinant IDE-mediated fluorescein-Abeta-(1-40)-Lys-biotin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 23nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 26nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 38nMAssay Description:Inhibition of human recombinant IDE-mediated insulin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 44nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 50nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 70nMAssay Description:Inhibition of human recombinant IDE-mediated fluorescein-Abeta-(1-40)-Lys-biotin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 73nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 78nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 85nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 87nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 103nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 107nMAssay Description:Inhibition of human recombinant IDE-mediated fluorescein-Abeta-(1-40)-Lys-biotin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 171nMAssay Description:Inhibition of human recombinant IDE-mediated insulin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 228nMAssay Description:Inhibition of human recombinant IDE-mediated fluorescein-Abeta-(1-40)-Lys-biotin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 246nMAssay Description:Inhibition of human recombinant IDE-mediated fluorescein-Abeta-(1-40)-Lys-biotin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 275nMAssay Description:Inhibition of human recombinant IDE-mediated insulin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 365nMAssay Description:Inhibition of human recombinant IDE-mediated fluorescein-Abeta-(1-40)-Lys-biotin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 410nMAssay Description:Inhibition of human recombinant IDE-mediated insulin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 498nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 833nMAssay Description:Inhibition of human recombinant IDE-mediated insulin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 927nMAssay Description:Inhibition of human recombinant IDE-mediated fluorescein-Abeta-(1-40)-Lys-biotin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 1.15E+3nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 1.28E+3nMAssay Description:Inhibition of human recombinant IDE-mediated insulin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 1.89E+3nMAssay Description:Inhibition of human recombinant IDE-mediated insulin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 3.26E+3nMAssay Description:Inhibition of human recombinant IDE-mediated insulin degradationMore data for this Ligand-Target Pair
Affinity DataKi: 5.28E+3nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 7.02E+3nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 7.75E+3nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 1.80E+4nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: >3.30E+4nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: >3.30E+4nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: >3.30E+4nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: >3.30E+4nMAssay Description:Inhibition of human recombinant IDE-mediated FRET1 degradationMore data for this Ligand-Target Pair
Affinity DataKi: 5.76E+4nM ΔG°: -24.2kJ/molepH: 8.0 T: 2°CAssay Description:In vitro lipoxygenase inhibition assay, lipoxygenase inhibiting activity was convenintly measured by slightly modifying the spectrometic method devel...More data for this Ligand-Target Pair
Affinity DataKi: 7.17E+4nM ΔG°: -23.7kJ/molepH: 8.0 T: 2°CAssay Description:In vitro lipoxygenase inhibition assay, lipoxygenase inhibiting activity was convenintly measured by slightly modifying the spectrometic method devel...More data for this Ligand-Target Pair
Affinity DataIC50: 1.15E+3nMAssay Description:Inhibition of MMP7 (unknown origin)-mediated omniMMP degradationMore data for this Ligand-Target Pair
Affinity DataIC50: 1.72E+3nMpH: 6.8 T: 2°CAssay Description:Tyrosinase inhibition assays were performed in a 96-well microplate format using SpectraMax 340 (Molecular Devices, CA, USA) microplate reader accord...More data for this Ligand-Target Pair
Affinity DataIC50: 3.68E+3nMpH: 6.8 T: 2°CAssay Description:Tyrosinase inhibition assays were performed in a 96-well microplate format using SpectraMax 340 (Molecular Devices, CA, USA) microplate reader accord...More data for this Ligand-Target Pair
Affinity DataIC50: 6.64E+3nMpH: 6.8 T: 2°CAssay Description:Tyrosinase inhibition assays were performed in a 96-well microplate format using SpectraMax 340 (Molecular Devices, CA, USA) microplate reader accord...More data for this Ligand-Target Pair
Affinity DataIC50: 7.80E+3nMpH: 8.0 T: 2°CAssay Description:In vitro liposygenase inhibition assay activity was measured by modifying the spectrophotometric method developed by Tappel. The compound was prepar...More data for this Ligand-Target Pair
Affinity DataIC50: 8.76E+3nMpH: 6.8 T: 2°CAssay Description:Tyrosinase inhibition assays were performed in a 96-well microplate format using SpectraMax 340 (Molecular Devices, CA, USA) microplate reader accord...More data for this Ligand-Target Pair
Affinity DataIC50: 1.25E+4nMpH: 8.0 T: 2°CAssay Description:In vitro liposygenase inhibition assay activity was measured by modifying the spectrophotometric method developed by Tappel. The compound was prepar...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+4nMpH: 8.0 T: 2°CAssay Description:In vitro cholinesterase inhibition assay using electric-eel acetylcholinesterase, horse-serum butyrylcholinesterse. The IC50 values were calculated ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.63E+4nMpH: 8.0 T: 2°CAssay Description:In vitro liposygenase inhibition assay activity was measured by modifying the spectrophotometric method developed by Tappel. The compound was prepar...More data for this Ligand-Target Pair
Affinity DataIC50: 1.67E+4nMpH: 6.8 T: 2°CAssay Description:Tyrosinase inhibition assays were performed in a 96-well microplate format using SpectraMax 340 (Molecular Devices, CA, USA) microplate reader accord...More data for this Ligand-Target Pair
Affinity DataIC50: 1.75E+4nMpH: 8.0 T: 2°CAssay Description:In vitro liposygenase inhibition assay activity was measured by modifying the spectrophotometric method developed by Tappel. The compound was prepar...More data for this Ligand-Target Pair
Affinity DataIC50: 1.81E+4nMpH: 6.8 T: 2°CAssay Description:Tyrosinase inhibition assays were performed in a 96-well microplate format using SpectraMax 340 (Molecular Devices, CA, USA) microplate reader accord...More data for this Ligand-Target Pair